Health technology assessment at age 25-Squaring the circle of strong methodology and context-dependency?

[1]  Kristian Lampe,et al.  Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA , 2009, International Journal of Technology Assessment in Health Care.

[2]  What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. , 2019, Health policy.

[3]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[4]  S. Ikeda,et al.  New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations. , 2017, Health policy.

[5]  Nika Murovec,et al.  Questioning the differences between general public vs. patient based preferences towards EQ-5D-5L defined hypothetical health states. , 2017, Health policy.

[6]  P. Kanavos,et al.  Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. , 2019, Health policy.

[7]  M. Trapero-Bertran,et al.  Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases? , 2019, Health policy.

[8]  H. Banta,et al.  Lessons from the eight countries. , 1994, Health policy.

[9]  R. Busse,et al.  Developing Health Technology Assessment to address health care system needs. , 2010, Health policy.

[10]  N. Allen,et al.  Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems. , 2013, Health policy.

[11]  P. Kanavos,et al.  Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. , 2019, Health policy.

[12]  H. Banta.  Health care technology as a policy issue. , 1994, Health policy.

[13]  L. Annemans,et al.  HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. , 2017, Health policy.

[14]  R. Busse.  Assessing the benefit of new pharmaceuticals: Are we talking the same language, can we explain disagreement, and would it be better to do it together? , 2016, Health policy.

[15]  R. Busse,et al.  HTA of medical devices: Challenges and ideas for the future from a European perspective. , 2017, Health policy.

[16]  Claudia Wild,et al.  BEST PRACTICE IN UNDERTAKING AND REPORTING HEALTH TECHNOLOGY ASSESSMENTS , 2002, International Journal of Technology Assessment in Health Care.

[17]  W. D. Wranik,et al.  Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland. , 2019, Health policy.

[18]  R. Busse,et al.  Testing a new taxonomic model for the assessment of medical devices: Is it plausible and applicable? Insights from HTA reports and interviews with HTA institutions in Europe. , 2019, Health policy.

[19]  Melissa Koch,et al.  Enabling health technology innovation in Canada: Barriers and facilitators in policy and regulatory processes. , 2019, Health policy.